- Tytuł:
- Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
- Autorzy:
- Źródło:
- In The Lancet Oncology March 2024 25(3):376-387
Czasopismo naukowe